This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $221,805 to the University of California, Davis (UC Davis) to study the effects of maternal immune activation (MIA) on brain and behavioral development in a non-human primate (NHP) model. The research aims to: 1) evaluate alterations in socioemotional behavior in MIA-exposed NHPs, 2) longitudinally map the...
This federal Project Grant award, valued at $219,456 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how sterile inflammation at the maternal-fetal interface impacts the developing fetal immune system. The project aims to test the hypothesis that injecting the clotting agent Tisseel into the maternal-fetal interface of pregnant rhesus macaques will induce...
This federal Project Grant award for $664,837, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify newborns with in-utero SARS-CoV-2 infection and assess their long-term immune response and clinical outcomes. The key objectives are to: 1) Utilize a multi-faceted approach, including antibody testing and SARS-CoV-2 PCR on cord blood, meconium/stool, and placentas, to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $793,102 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Wake Forest University Health Sciences (WFUHS) to investigate the interplay of maternal antibody and newborn vaccine responses for influenza virus. The goal is to effectively vaccinate young infants when maternal antibody is at high levels, such that as maternal antibody wanes, a protective anti-influenza response rises...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to characterize the early childhood neurodevelopmental impact of infants exposed to maternal SARS-CoV-2 infection during pregnancy. The $324,464 award, granted on July 16, 2024, will fund research conducted by the Ann & Robert H. Lurie Children's Hospital of Chicago. The key objectives are to: 1) perform...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $402,731.00 in funding over a 5-year period from March 1, 2025 to February 28, 2030. The objective is to increase the number of next-generation physician-scientists who can apply knowledge of microbiology, immunology, and research techniques to improve reproductive, maternal, and child health. The funding will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $556,002 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant will fund research aimed at defining the mechanistic features of interleukin-27 (IL-27) signaling at the maternal-fetal interface and its protective capacity during congenital infection....
This federal Project Grant award of $799,017.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to define the function and distribution of natural killer (NK) cells in tissues from SIV-infected, ART-treated rhesus macaques after IL-21 administration. The research aims to evaluate if IL-21-induced terminally-differentiated NK cells can be durably prolonged after analytical...
This $2,065,600.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to investigate the complex relationships between pre-existing immunity to different flaviviruses and subsequent infection outcomes. The award will integrate studies in non-human primate models and human cohorts to evaluate the impact of flavivirus exposure on antibody repertoire diversity, neutralization, and Fc effector...
This $769,115 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at The Washington University in St. Louis aimed at advancing the mechanistic understanding of how meningeal structures function in regulating and responding to neurotropic virus infections. The key research objectives are to: 1) Define the role of arachnoid cuff exit (ACE) points in enabling...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the impact of maternal viral infections and inflammation on immune programming within the fetal brain and lymphoid organs in a non-human primate model. The $3,305,720 award, granted on July 12, 2024, with a completion date of May 31, 2029, will be used to: 1) Determine innate immune pathways activated by model viruses, type I interferon, IL-6, and TNF-alpha in fetal brain and lymphoid organs during the first and third trimesters using an ex vivo microculture model; and 2) Link the profile of fetal innate and adaptive immune activation with the production of alarmins and induction of the autophagic response in the fetal brain using a pregnant non-human primate model of acute Zika virus infection. This research aims to reveal gene networks of innate immune programming that direct viral and inflammatory injury of major fetal organs, which can inform therapeutic approaches for fetal neuroprotection.